ストックスクリーナーアプリを入手
15.10
1.92%
-0.2835
前日終値:
$15.38
開ける：
$15.07
24時間の取引高:
437.99K
Relative Volume:
0.17
時価総額：
$11.71B
収益：
$220.00K
当期純損益:
$-1.08B
株価収益率:
-10.45
EPS:
-1.4448
ネットキャッシュフロー:
$-326.53M
1週間 パフォーマンス:
-4.53%
1か月 パフォーマンス:
+8.92%
6か月 パフォーマンス:
-41.94%
1年 パフォーマンス:
-22.84%
1日の値動き範囲:
$14.90
$15.15
1週間の範囲:
$14.90
$16.61
52週間の値動き範囲:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.11 | 11.93B | 220.00K | -1.08B | -326.53M | -1.4448 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.95 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.60 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-09-17 | 開始されました | Barclays | Underweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Neutral |
| 2025-07-01 | 開始されました | UBS | Buy |
| 2025-06-11 | 開始されました | Leerink Partners | Underperform |
| 2025-03-26 | アップグレード | Citigroup | Neutral → Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 開始されました | Evercore ISI | Outperform |
| 2025-02-28 | 開始されました | Goldman | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
10 Stocks With Explosive Growth Potential - Insider Monkey
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Innovator with an 89.92% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab - Insider Monkey
The Technical Signals Behind (SMMT) That Institutions Follow - Stock Traders Daily
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Q1 EPS Estimate for Summit Therapeutics Increased by Analyst - MarketBeat
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
How Summit’s Deeper 2025 Loss and Ivonescimab’s FDA Path At Summit Therapeutics (SMMT) Has Changed Its Investment Story - simplywall.st
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty - Investing.com Australia
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | - GuruFocus
Traders Purchase High Volume of Put Options on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Yahoo Finance
Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
HC Wainwright Has Lowered Expectations for Summit Therapeutics (NASDAQ:SMMT) Stock Price - MarketBeat
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Q4 Earnings Miss Expectations - GuruFocus
Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus
Summit Therapeutics (SMMT) Highlights Progress in Cancer Drug De - GuruFocus
Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf RegistrationHas The Bull Case Changed? - Yahoo Finance
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss - Investing.com Nigeria
Summit Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Summit Therapeutics (SMMT) Updates on HARMONi-3 Trial Progress - GuruFocus
Summit Therapeutics falls on earnings miss despite progress By Investing.com - Investing.com South Africa
Summit Therapeutics falls on earnings miss despite progress - Investing.com
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks
Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise - marketscreener.com
Summit Therapeutics Inc. SEC 10-K Report - TradingView
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09 - marketscreener.com
Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Summit Therapeutics: Q4 Earnings Insights - Benzinga
Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - ChartMill
Summit Therapeutics (SMMT) Shows Elevated Options Activity Ahead of Earnings - GuruFocus
Highs Report: Can Summit Therapeutics Inc stock outperform in a bear marketJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Summit Therapeutics Set to Announce Q4 Earnings on February 23 - Intellectia AI
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
Summit Therapeutics Inc (SMMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.50%
大文字化:
|
ボリューム (24 時間):